|
Malignant neoplasm of breast
|
|
0.780 |
GeneticVariation
|
BEFREE |
To better understand the molecular basis for trafficking defects that trap caveolin-1 intracellularly, we compared the properties of a GFP-tagged version of caveolin-1 P132L, a mutant form of caveolin-1 previously linked to breast cancer, with wild-type caveolin-1.
|
23469926 |
2013 |
|
Malignant neoplasm of breast
|
|
0.780 |
GeneticVariation
|
BEFREE |
None of the reported CAV1 gene mutations, including CAV1 (P132L), were identified in either clinical samples (95% CI: 0-1.5%) or human breast cancer cell lines analysed.
|
21909981 |
2012 |
|
Malignant neoplasm of breast
|
|
0.780 |
GeneticVariation
|
BEFREE |
These results raise doubt about the presence of the caveolin-1 P132L mutation in breast cancer and other cancer types, and thus further studies are warranted.
|
20581046 |
2010 |
|
Malignant neoplasm of breast
|
|
0.780 |
GeneticVariation
|
BEFREE |
Caveolin-1 (Cav-1) mutations, such as P132L, are associated with ER-positive human breast cancers.
|
19342880 |
2009 |
|
Malignant neoplasm of breast
|
|
0.780 |
GeneticVariation
|
BEFREE |
Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature.
|
19395651 |
2009 |
|
Malignant neoplasm of breast
|
|
0.780 |
GeneticVariation
|
BEFREE |
We report that the Cav-1 P132L mutation is present in approximately 19% of estrogen receptor alpha (ERalpha)-positive breast cancers but not in ERalpha-negative breast cancers.
|
16723714 |
2006 |
|
Malignant neoplasm of breast
|
|
0.780 |
GeneticVariation
|
BEFREE |
Genetic evidence from the study of Cav-1(-/-) null mice and human breast cancer mutations [CAV-1 (P132L)] supports the idea that caveolin-1 normally functions as a negative regulator of cell transformation and mammary tumorigenesis.
|
15692148 |
2005 |
|
Malignant neoplasm of breast
|
|
0.780 |
GeneticVariation
|
BEFREE |
To understand the role of the Cav-1 (P132L) mutation in the pathogenesis of human breast cancers, we generated the same mutation in wild-type (WT) Cav-1 and studied its behavior in cultured cells.
|
12368209 |
2002 |
|
Malignant neoplasm of breast
|
|
0.780 |
GeneticVariation
|
UNIPROT |
|
|
|
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
To better understand the molecular basis for trafficking defects that trap caveolin-1 intracellularly, we compared the properties of a GFP-tagged version of caveolin-1 P132L, a mutant form of caveolin-1 previously linked to breast cancer, with wild-type caveolin-1.
|
23469926 |
2013 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
None of the reported CAV1 gene mutations, including CAV1 (P132L), were identified in either clinical samples (95% CI: 0-1.5%) or human breast cancer cell lines analysed.
|
21909981 |
2012 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
These results raise doubt about the presence of the caveolin-1 P132L mutation in breast cancer and other cancer types, and thus further studies are warranted.
|
20581046 |
2010 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Caveolin-1 (P132L), a common breast cancer mutation, confers mammary cell invasiveness and defines a novel stem cell/metastasis-associated gene signature.
|
19395651 |
2009 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Genetic evidence from the study of Cav-1(-/-) null mice and human breast cancer mutations [CAV-1 (P132L)] supports the idea that caveolin-1 normally functions as a negative regulator of cell transformation and mammary tumorigenesis.
|
15692148 |
2005 |
|
Breast Carcinoma
|
|
0.060 |
GeneticVariation
|
BEFREE |
Caveolin-1 mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 (-/-) null mice show mammary epithelial cell hyperplasia.
|
12368209 |
2002 |
|
Bronchioloalveolar Adenocarcinoma
|
|
0.010 |
GeneticVariation
|
BEFREE |
A strong cytoplasmic expression of Cav1 correlated with poor survival in a small subgroup (n = 5) of BAC patients, and stable expression of an oncogenic Cav1 variant (Cav1-P132L) in the human BAC cell line OE19 promoted proliferation.
|
22474125 |
2012 |
|
Malignant Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
These results raise doubt about the presence of the caveolin-1 P132L mutation in breast cancer and other cancer types, and thus further studies are warranted.
|
20581046 |
2010 |
|
Primary malignant neoplasm
|
|
0.010 |
GeneticVariation
|
BEFREE |
These results raise doubt about the presence of the caveolin-1 P132L mutation in breast cancer and other cancer types, and thus further studies are warranted.
|
20581046 |
2010 |
|
Mammary Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
Even when using this sensitive method, none of the 80 estrogen receptor-positive breast tumors had the P132L mutation.
|
20581046 |
2010 |
|
Neoplasm Metastasis
|
|
0.010 |
GeneticVariation
|
BEFREE |
From this analysis, we show that the Cav-1(P132L) expression signature contains numerous genes that have been previously associated with cell migration, invasion, and metastasis.
|
19395651 |
2009 |
|
Tumor Cell Invasion
|
|
0.010 |
GeneticVariation
|
BEFREE |
From this analysis, we show that the Cav-1(P132L) expression signature contains numerous genes that have been previously associated with cell migration, invasion, and metastasis.
|
19395651 |
2009 |
|
Neoplasms
|
|
0.010 |
GeneticVariation
|
BEFREE |
This is the first demonstration that the P132L mutation is exclusively associated with ERalpha-positive mammary tumors.
|
16723714 |
2006 |